Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMDNASDAQ:NURONASDAQ:PYPDNASDAQ:RSLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.25-35.6%$2.66$1.06▼$8.44$3.24M1.89195,515 shs1.00 million shsNURONeuroMetrix$4.55+4.4%$4.52$2.66▼$4.73$9.37M1.8216,349 shs35,522 shsPYPDPolyPid$3.57-0.3%$3.01$2.30▼$4.95$36.38M1.25131,282 shs104,784 shsRSLSReShape Lifesciences$2.44+2.5%$5.65$2.23▼$414.99$5.83M1.29784,238 shs440,134 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical0.00%-20.89%-56.62%-56.35%-68.67%NURONeuroMetrix0.00%0.00%0.00%+1.22%+23.31%PYPDPolyPid0.00%+8.84%+25.70%+31.73%-16.98%RSLSReShape Lifesciences0.00%-4.31%-49.17%-72.93%-99.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical2.5755 of 5 stars3.53.00.00.02.30.01.3NURONeuroMetrixN/AN/AN/AN/AN/AN/AN/AN/APYPDPolyPid2.7052 of 5 stars3.63.00.00.03.31.70.0RSLSReShape Lifesciences0.1191 of 5 stars0.02.00.00.01.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 3.00Buy$56.004,380.00% UpsideNURONeuroMetrix 0.00N/AN/AN/APYPDPolyPid 3.17Buy$11.80230.53% UpsideRSLSReShape Lifesciences 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest NURO, PYPD, AEMD, and RSLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $9.006/17/2025PYPDPolyPidJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $14.006/9/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.006/5/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.006/2/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$11.004/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K5.68N/AN/A$2.55 per share0.49NURONeuroMetrix$3.03M3.09N/AN/A$13.18 per share0.35PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ARSLSReShape Lifesciences$8.01M0.73N/AN/A($8.66) per share-0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$13.39M-$12.64N/AN/AN/AN/A-221.38%-156.83%8/12/2025 (Estimated)NURONeuroMetrix-$6.53M-$4.59N/A∞N/A-203.71%-42.56%-39.26%8/4/2025 (Estimated)PYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-1,069.37%-151.85%8/13/2025 (Estimated)RSLSReShape Lifesciences-$7.13M-$193.23N/A∞N/A-48.26%-251.90%-59.49%8/12/2025 (Estimated)Latest NURO, PYPD, AEMD, and RSLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025RSLSReShape LifesciencesN/A$18.98N/A$18.98N/A$1.11 million5/14/2025Q1 2025PYPDPolyPid-$0.80-$0.70+$0.10-$0.70N/AN/A4/4/2025Q4 2024RSLSReShape Lifesciences-$101.50-$47.25+$54.25-$1.89$3.17 million$1.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/ANURONeuroMetrixN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ARSLSReShape LifesciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A3.133.13NURONeuroMetrixN/A13.8812.70PYPDPolyPid4.430.710.71RSLSReShape LifesciencesN/A1.530.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%NURONeuroMetrix19.40%PYPDPolyPid26.47%RSLSReShape Lifesciences22.06%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical1.20%NURONeuroMetrix7.30%PYPDPolyPid24.70%RSLSReShape Lifesciences0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical102.59 million2.55 millionNo DataNURONeuroMetrix202.06 million1.90 millionNot OptionablePYPDPolyPid8010.19 million7.67 millionNo DataRSLSReShape Lifesciences502.39 million2.39 millionNot OptionableNURO, PYPD, AEMD, and RSLS HeadlinesRecent News About These CompaniesReShape Lifesciences Inc (RSLS) Stock Forums - Investing.comJune 28 at 6:18 PM | investing.comReShape Lifesciences Inc: ReShape Lifesciences Regains Compliance with Nasdaq Minimum Stockholders Equity RequirementJune 27 at 7:18 PM | finanznachrichten.deReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with ... - MorningstarJune 27 at 7:18 PM | morningstar.comMReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity RequirementJune 27 at 9:01 AM | globenewswire.comRSLS - Reshape Lifesciences Inc Executives - MorningstarJune 26, 2025 | morningstar.comMRSLS - Reshape Lifesciences Inc Valuation - MorningstarJune 26, 2025 | morningstar.comMReShape Lifesciences receives Australian patent for diabetes deviceJune 26, 2025 | investing.comReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad MedisysJune 26, 2025 | globenewswire.comReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation TechnologyJune 25, 2025 | globenewswire.comReShape Lifesciences Raises Equity to Avoid DelistingJune 18, 2025 | tipranks.comReShape Lifesciences Stock Soars On Distribution Agreement With Recon Supply, Draws Retail ApplauseJune 13, 2025 | msn.comReShape Lifesciences Inc: ReShape Lifesciences Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD MarketsJune 12, 2025 | finanznachrichten.deReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD MarketsJune 12, 2025 | globenewswire.comReShape Lifesciences® Announces Pricing of Public Offering of Common Stock Raising Approximately $2.6 MillionJune 11, 2025 | nasdaq.comReShape Lifesciences Stock Slumps As Company Prices Public Offering At Significant Discount: Retail Holds On To OptimismJune 10, 2025 | msn.comReShape Lifesciences® Announces Pricing of $2.6 Million Public OfferingJune 9, 2025 | globenewswire.comReShape Lifesciences Stock Soars On Regulatory Certification For Medical Devices In EU, UK: Retail Eyes Fair ValuationJune 4, 2025 | msn.comReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product PortfolioJune 3, 2025 | globenewswire.comReShape Lifesciences announces merger progressMay 30, 2025 | uk.investing.comReShape Lifesciences Inc. Reports First Quarter 2025 Financial Results and Strategic UpdatesMay 21, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNURO, PYPD, AEMD, and RSLS Company DescriptionsAethlon Medical NASDAQ:AEMD$1.25 -0.69 (-35.57%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.23 -0.02 (-1.52%) As of 05:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.NeuroMetrix NASDAQ:NURO$4.55 +0.19 (+4.36%) Closing price 05/1/2025Extended Trading$4.55 0.00 (0.00%) As of 05/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.PolyPid NASDAQ:PYPD$3.57 -0.01 (-0.28%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.55 -0.02 (-0.67%) As of 05:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.ReShape Lifesciences NASDAQ:RSLS$2.44 +0.06 (+2.52%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.47 +0.03 (+1.23%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
